Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of KL-A167 plus cisplatin and gemcitabine versus placebo plus cisplatin and gemcitabine in recurrent or metastatic nasopharyngeal carcinoma
CTR20220691Phase 3Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nasopharyngeal carcinoma (NPC) comparing KL-A167 + cisplatin + gemcitabine with Placebo + cisplatin + gemcitabine (2 arms). Primary endpoint: Progression-free survival by independent radiologic review committee using RECIST 1.1. Started Jun 2022; status: active.
02
Drugs
tagitanlimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20220691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220691.